Institutional investors purchased a net $3.1 million shares of HALO during the quarter ended June 2016. This may signal that the smart money is gaining interest in this company as the 67.67% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CANDRIAM BELGIUM SA Bought 60.0 Thousand shares of Halozyme Therapeutics Inc
CUTLER GROUP LP Bought 11.7 Thousand shares of Halozyme Therapeutics Inc